Navigation Links
Nventa Biopharmaceuticals Announces Third Quarter 2008 Financial Results and Recent Corporate Highlights
Date:11/11/2008

12,859,000, as of December 31, 2007.

About Nventa Biopharmaceuticals Corporation:

Nventa is developing innovative therapeutics incorporating our proprietary CoVal(TM) fusion technology for the treatment of viral infections and cancers, with a focus on diseases caused by the human papillomavirus (HPV); and a Toll- like Receptor 3 (TLR3) agonist for use as a vaccine adjuvant and as an immunotherapeutic for viral infections and cancer. The company is publicly traded on the Toronto Stock Exchange under the symbol "NVN". For more information about Nventa Biopharmaceuticals Corporation, please visit the company's website located at http://www.nventacorp.com.

The audit committee of the company has reviewed and approved of the contents of this press release. Summary financial statements are attached below. The full financial statements and MD&A for the three and nine months ended September 30, 2008 can be found on SEDAR at http://www.sedar.com.

This press release contains statements which may constitute forward- looking information under applicable Canadian securities legislation or forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking statements or information may include financial and other projections as well as statements regarding the company's future plans, objectives, performance, revenues, growth, profits, operating expenses or the company's underlying assumptions. The words "may", "would", "could", "will", "likely", "expect," "anticipate," "intend", "plan", "forecast", "project", "estimate" and "believe" or other similar words and phrases may identify forward-looking statements or information. Persons reading this press release are cautioned that such statements or information are only expectations, and that the company's actual future results or perform
'/>"/>

SOURCE Nventa Biopharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
2. Nventa announces publication of HspE7 data
3. Nventas CEO to present at two upcoming investor conferences
4. Nventa updates progress of cervical dysplasia trial with new HspE7
5. Nventa Biopharmaceuticals Corporation announces third-quarter 2007 financial results
6. Nventa completes enrollment and initial dosing of second cohort in Phase 1 HspE7 safety trial
7. Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results
8. Nventa Appoints John Varian to Board of Directors
9. Nventa Appoints Gordon H. Busenbark to Board of Directors
10. Nventa Provides Corporate Update and Advancement Plans for HspE7, Hsp 6/11 and Poly-ICR
11. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... April 1, 2015 Synthetic Biologics, Inc. ... for serious infections and diseases, with a focus ... data supporting the development of SYN-004, the Company,s ... (IV) antibiotics within the gastrointestinal (GI) tract and ... for the prevention of C. difficile ...
(Date:4/1/2015)... Holomic is introducing the HRDR-400, the first ... fluorescent rapid tests with one device. , Holomic ... and is already selling its HRDR-200 chromatographic and HRDR-300 ... its kind offering for manufacturers and end-users that need ... Karlovac, CEO of Holomic LLC, commented, "We are responding ...
(Date:4/1/2015)... 2015  Spherix Incorporated (Nasdaq: SPEX ) -- an ... and monetization of intellectual property, today announced that ... service global investment bank specializing in micro, small, ... featuring Spherix. The report, authored by ... at Chardan, was published on March 31, 2015. ...
(Date:4/1/2015)... WASHINGTON and NEW YORK CITY ... As a leading provider of market research reports ... BioInformant Worldwide, LLC, indicating that 2015 will be a year ... For executives operating a stem cell company or ... a difficult task. You must analyze market conditions, predict industry ...
Breaking Biology Technology:Synthetic Biologics' SYN-004 Clinical Data for Protection of Microbiome Selected for Poster Presentation at American Society of Microbiology 2015 2Synthetic Biologics' SYN-004 Clinical Data for Protection of Microbiome Selected for Poster Presentation at American Society of Microbiology 2015 3Synthetic Biologics' SYN-004 Clinical Data for Protection of Microbiome Selected for Poster Presentation at American Society of Microbiology 2015 4Holomic to Introduce the First Dual, Chromatographic and Fluorescent Rapid Test Reader, the HRDR-400 2Chardan Capital Issues Industry Note Covering Spherix 2Chardan Capital Issues Industry Note Covering Spherix 3MarketResearch.com: "Blockbuster" Year for Stem Cells Creates Market Opportunities, Says BioInformant Worldwide Report 2MarketResearch.com: "Blockbuster" Year for Stem Cells Creates Market Opportunities, Says BioInformant Worldwide Report 3MarketResearch.com: "Blockbuster" Year for Stem Cells Creates Market Opportunities, Says BioInformant Worldwide Report 4
... DIEGO, Sept. 13 Genomatica announced today ... the company full time as executive chairman and chief ... with leading chemical producers, users, feedstock suppliers, brands and ... and biotech leadership; $500 million in partnerships ...
... Convergent Procedure, a novel approach to treat atrial ... nContact Surgical, Inc. (nContact), was highlighted at the ... Association for Cardio-Thoracic Surgery) Annual Meeting in Geneva, ... 2010 Techno-College Programme to receive an update on ...
... Berkeley, have developed a pressure-sensitive electronic material from semiconductor ... the term "thin-skinned." "The idea is to ... which means incorporating the ability to feel and touch ... and computer sciences and head of the UC Berkeley ...
Cached Biology Technology:Bill Baum Joins Genomatica as it Ramps for Commercial Rollout 2Bill Baum Joins Genomatica as it Ramps for Commercial Rollout 3Bill Baum Joins Genomatica as it Ramps for Commercial Rollout 4The Convergent Procedure for the Treatment of Chronic Atrial Fibrillation Highlighted at EACTS Annual Meeting in Geneva 2Engineers make artificial skin out of nanowires 2Engineers make artificial skin out of nanowires 3
(Date:3/31/2015)...  Elephant Talk Communications Corp. (NYSE MKT: ETAK) ("Elephant ... Defined Network Architecture (ET Software DNA® 2.0) platforms and ... $20.4 million for the year ended December 31, 2014 ... year ended December 31, 2013. At ... its multi-year transition away from its legacy landline business ...
(Date:3/31/2015)... YORK , March 31, 2015   Guidepoint ... the launch of the Post-Surgical Pain Management TRACKER, part ... products tracking usage trends in the medical device and ... access to data including treatment volumes, market share, and ... the pain associated with joint surgery. The ...
(Date:3/30/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/lc9bnl/global_gesture ... Gesture Recognition Market in Automotive Sector 2014-2018" report ... Global Gesture Recognition market in Automotive Sector to grow ... Gesture recognition is the ability of a ... an individual. Gesture recognition technology can be 2D-based or ...
Breaking Biology News(10 mins):Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2
... Researchers at the RIKEN Plant Science Center (PSC) have ... in the model plant Arabidopsis protects cells from harmful ... the journal PLoS Genetics , the finding contributes ... biological processes in both plants and animals, opening the ...
... seals often encounter murky water that impedes their vision; ... Extending their vibration-sensitive whiskers, the mammals are almost as ... if guided by sight. Wolf Hanke and his colleagues ... how harbour seals perceive the world through their flow-sensitive ...
... 2011 UT Southwestern Medical Center researchers have discovered a ... to a treatment to keep cancer cells from spreading. ... 1 (Rasip1) is so specific and central to so many ... form, said Dr. Ondine Cleaver, assistant professor of molecular biology ...
Cached Biology News:Discovery of DNA silencing mechanism reveals how plants protect their genome 2Seals sense shapes using their whiskers to feel wakes 2UT Southwestern researchers find protein that might be key to cutting cancer cells' blood supply 2